A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

PURPOSE: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/ MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC. PATIENTS AND METHODS: Patients...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Kurzrock, Razelle, Ball, Douglas W., Zahurak, Marianna L., Nelkin, Barry D., Subbiah, Vivek, Ahmed, Shabina, O’Connor, Ashley, Karunsena, Enusha, Parkinson, Rose M., Bishop, Justin A., Ha, Yoonji, Sharma, Rajni, Gocke, Christopher D., Zinner, Ralph, Rudek, Michelle A., Sherman, Steven I., Azad, Nilofer S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038784/
https://ncbi.nlm.nih.gov/pubmed/31186313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1881
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares